DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Emma Hall, Johann S. de Bono et al.|New England Journal of Medicine|2015Cited by 2.2k
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumoursSarah P. Blagden, Mark R. Middleton, L. Rhoda Molife et al.|British Journal of Cancer|2008Cited by 82
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug ResponsePing Zhang, Gareth L. Bond, Isaac Kitchen-Smith et al.|Cancer Research|2021Cited by 49
<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>Eliana MC Tacconi, Andrew Protheroe|OncoTargets and Therapy|2020Cited by 30